Skip to main content
Clinical Trials/NL-OMON50021
NL-OMON50021
Recruiting
Not Applicable

Establishing biomarkers and clinical endpoints in myotonic dystrophy type 1 (END-DM1) - Establishing biomarkers and clinical endpoints in DM type 1

Radboud Universitair Medisch Centrum0 sites20 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
DM1
Sponsor
Radboud Universitair Medisch Centrum
Enrollment
20
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational non invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • \- Age 18 to 70 years (inclusive)
  • \- Competent to provide informed consent
  • \- Clinical diagnosis of DM1 based on research criteria or positive genetic test

Exclusion Criteria

  • \- Symptomatic renal or liver disease, uncontrolled diabetes or thyroid
  • disorder, or active malignancy other than skin cancer
  • \- Current alcohol or substance abuse
  • \- Concurrent enrollment in clinical trial for DM1, pr participation in trial
  • within 6 months of entry
  • \- Concurrent pregnancy or planned pregnancy during the course of the study
  • \- Concurrent medical condition that would, in the opinion of the investigator
  • or clinical evaluator, compromise performance on study measures
  • \- Use of mexiletine or other anti\-myotonia agents within 72 hours of baseline
  • Note: non\-ambulatory participants are not excluded but are limited to \<15% of

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Development of surrogate end-point biomarkers for chronic fatigue and myalgic encephalmyelitis/chronic fatigue syndrome ( ME/CFS)
JPRN-UMIN000029076Osaka City University120
Recruiting
Not Applicable
Exploring Predictive and Prognostic Biomarkers in People with Cancer.CancerCancer - Any cancer
ACTRN12623000853640Monash Health500
Recruiting
Not Applicable
Identifying and validating predictive and prognostic biomarkers in male Germ Cell Tumours to improve the management and outcomes in both stage 1 and disseminated disease.Germ Cell Tumour (GCT)SeminomaTesticular cancerCancer - Testicular
ACTRN12618000931279Walter and Eliza Hall Institute for Medical Research800
Not yet recruiting
Not Applicable
Biomarkers in Pancreatic CancerHistologically or cytologically confirmed pancreatic cancerCancer - Pancreatic
ACTRN12616000519459The Walter and Eliza Hall Institute of Medical Research500
Recruiting
Not Applicable
Clinical, molecular and functional biomarkers for PROgnosis, pathomechanisms and treatment strategies of COVID-19 (PROVID) - (PROVID-CAPNETZ)Coronavirus Disease 19 (COVID-19)U07.1J12J13J14J15J16J17J18COVID-19, virus identifiedViral pneumonia, not elsewhere classifiedPneumonia due to Streptococcus pneumoniaePneumonia due to Haemophilus influenzaeBacterial pneumonia, not elsewhere classifiedPneumonia due to other infectious organisms, not elsewhere classifiedPneumonia in diseases classified elsewherePneumonia, organism unspecified
DRKS00022871CAPNETZ STIFTUNG, Geschäftsstelle an der Medizinischen Hochschule Hannover400